Фильтр :
Стандарт и/или проект | Этап | ТК |
---|---|---|
Biological evaluation of medical devices — Part 1: Evaluation and testing
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process — Technical Corrigendum 1
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 2: Animal welfare requirements
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 2: Animal welfare requirements
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 2: Animal welfare requirements
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 2: Animal welfare requirements
|
40.20 | ISO/TC 194 |
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1
|
50.00 | ISO/TC 194 |
Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity
|
90.93 | ISO/TC 194 |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals — Amendment 1: Applicability of allowable limits for neonates and infants
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals — Technical Corrigendum 1
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 8: Selection and qualification of reference materials for biological tests
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products
|
90.20 | ISO/TC 194 |
Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity — Amendment 1
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 10: Tests for skin sensitization
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials — Amendment 1
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 14: Identification and quantification of degradation products from ceramics
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys
|
90.20 | ISO/TC 194 |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents — Amendment 1
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 18: Chemical characterization of materials
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process — Amendment 1: Determination of the uncertainty factor
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 19: Physico-chemical, morphological and topographical characterization of materials
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Part 19: Physico-chemical, morphological and topographical characterization of materials
|
90.93 | ISO/TC 194 |
Biological evaluation of medical devices — Part 20: Principles and methods for immunotoxicology testing of medical devices
|
90.20 | ISO/TC 194 |
Biological evaluation of medical devices — Part 22: Guidance on nanomaterials
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 23: Tests for irritation
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 23: Tests for irritation — Amendment 1: Additional in vitro reconstructed human epidermis models
|
40.20 | ISO/TC 194 |
Biological evaluation of medical devices — Part 33: Guidance on tests to evaluate genotoxicity — Supplement to ISO 10993-3
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Part 55: Interlaboratory study on cytotoxicity
|
60.60 | ISO/TC 194 |
Biological evaluation of medical devices — Requirements for interlaboratory studies to demonstrate the applicability of validated in vitro methods to assess the skin sensitization of medical devices
|
60.60 | ISO/TC 194 |
Medical products containing viable human cells — Application of risk management and requirements for processing practices
|
90.93 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Part 1: General requirements
|
95.99 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Part 2: Clinical investigation plans
|
95.99 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Good clinical practice
|
95.99 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Good clinical practice — Technical Corrigendum 1
|
95.99 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Good clinical practice
|
90.92 | ISO/TC 194 |
Clinical investigation of medical devices for human subjects — Good clinical practice
|
40.60 | ISO/TC 194 |
Biological evaluation of medical devices — Guidance on the conduct of biological evaluation within a risk management process
|
95.99 | ISO/TC 194 |
Biological evaluation of medical devices — Guidance on the conduct of biological evaluation within a risk management process
|
95.99 | ISO/TC 194 |
Clinical laboratory testing — Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing
|
90.60 | ISO/TC 212 |
Clinical laboratory testing and in vitro medical devices — Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy
|
95.99 | ISO/TC 212 |
Clinical laboratory testing and in vitro medical devices — Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy
|
60.60 | ISO/TC 212 |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases
|
95.99 | ISO/TC 212 |
Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases
|
90.60 | ISO/TC 212 |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices
|
95.99 | ISO/TC 212 |
Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices against reference broth micro-dilution
|
60.60 | ISO/TC 212 |
Biological evaluation of medical devices — Guidance on a risk-management process
|
95.99 | ISO/TC 194 |
Pyrogenicity — Principles and methods for pyrogen testing of medical devices
|
90.92 | ISO/TC 194 |
Biological evaluation of medical devices — Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents
|
90.93 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management
|
95.99 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management
|
95.99 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management
|
60.60 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling
|
95.99 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling
|
95.99 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling
|
60.60 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents
|
90.92 | ISO/TC 194 |
Medical devices utilizing animal tissues and their derivatives — Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes
|
90.93 | ISO/TC 194 |
По запросу ничего не найдено. Пожалуйста, попробуйте изменить настройки фильтра.